Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 10/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16907822 | 0.89 | PTGIR (0.49) | BCHEMAOBACHEPTGIRNPC1 | |
| SCHEMBL6224442 | 0.88 | BCHE (0.48) | BCHEMAOBACHEPTGIRNPC1 | |
| SCHEMBL6421300 | 0.82 | CHRM3 (0.48) | BCHEMAOBACHEHDAC3HDAC1 | |
| SCHEMBL16468054 | 0.81 | HIF1A (0.41) | CA1CA2CA9 | |
| SCHEMBL22738206 | 0.78 | KMT2A (0.44) | ALDH1A1 | |
| SCHEMBL28602436 | 0.76 | CA1 (0.50) | NPC1ALDH1A1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL16612525 | 0.75 | RBP4 (0.43) | CA1CA2CA9 | |
| SCHEMBL21381109 | 0.74 | USP30 (0.41) | ACHE | |
| SCHEMBL17394174 | 0.74 | SMN1; SMN2 (0.55) | NPC1ALDH1A1RAB9ASMN1; SMN2CA1 | |
| SCHEMBL586426 | 0.74 | HIF1A (0.42) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | claimed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | claimed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | claimed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | claimed |
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2005-12-15 | — | — | US | disclosed |
| EP-1549278-A4 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1549278-A2 | M sb 3 /sb MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004012684-A2 | M3MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277676-A1 | M3muscarinic acetylcholine receptor antagonists | CHRM3, CHRM2, CHRM5 | BCHE 97/4885MAOB 1120/4885ACHE 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.